ライフサイエンスコーパス: yellow fever

1 and 38% were visiting countries endemic for yellow fever.

2 ncluding smallpox, polio, measles, mumps and yellow fever.

3 ored diseases such as bovine tuberculosis or yellow fever.

4 of Aedes aegypti, a mosquito that transmits yellow fever.

5 tuberculosis to 8043 (95% CI 7621-8464) for yellow fever.

6 mopolitan vector of dengue, chikungunya, and yellow fever.

7 there is no specific antiviral treatment for yellow fever.

8 tion during investigations on the ecology of yellow fever.

9 its derivatives as antiviral agents to treat yellow fever.

10 iral therapeutics for clinical management of yellow fever.

11 cases (rubella, -4.5% [95% CI -9.5 to -0.1]; yellow fever, 1.2% [-2.9 to 5.5]).

12 than candidates based on Langat E5, TBE, and yellow fever 17D backbones, and was found to be highly i

13 tracerebral (i.c.) route, whereas commercial yellow fever 17D vaccine (YF-Vax) caused lethal encephal

14 lated with the reference virus, a commercial yellow fever 17D vaccine (YF-VAX).

15 s for a human vaccine; it appears safer than yellow fever 17D vaccine but has a similar profile of im

16 and envelope (E) sequences inserted into the yellow fever 17D vaccine genome.

17 Yellow fever 17D vaccine is one of the most successful v

18 Viral encephalitis caused by neuroadapted yellow fever 17D virus (PYF) was studied in parental and

19 A molecular clone of mouse-neuroadapted yellow fever 17D virus (SPYF-MN) was used to identify cr

20 Serial passage of yellow fever 17D virus (YF5.2iv, derived from an infecti

21 irus (LGTV), a former live TBEV vaccine; and yellow fever 17D virus vaccine (YF 17D) in rhesus monkey

22 Live chimeric yellow fever 17D/TBE, Dengue 2/TBE, and Langat E5/TBE ca

23 ibodies elicited by the tetravalent chimeric yellow fever-17D/dengue vaccine or DENV infection.

24 aegypti mosquito, that also carries dengue, yellow fever and chikungunya viruses.

25 edes aegypti is the most important vector of yellow fever and dengue fever flaviviruses.

26 ome of Aedes aegypti, the primary vector for yellow fever and dengue fever, which at approximately 13

27 , a vector for the flaviviral agents causing Yellow fever and Dengue fever.

28 In the yellow fever and dengue vector Aedes aegypti, both sexes

29 he acquisition of the genome sequence of the yellow fever and Dengue vector, Aedes aegypti (Aa), has

30 , and asymptomatic infection predominates in yellow fever and dengue viral infections.

31 edes aegypti is the principal vector for the yellow fever and dengue viruses, and is also responsible

32 k-borne encephalitis, Japanese encephalitis, yellow fever and dengue viruses, constitute a significan

33 gens responsible for other diseases, such as yellow fever and dengue.

34 borne infectious diseases such as dengue and yellow fever and emerging diseases such as Zika and chik

35 Yellow fever and Japanese encephalitis vaccinees were le

36 elated to the human epidemic-causing dengue, yellow fever and Japanese encephalitis viruses.

37 o emergency situations, such as outbreaks of yellow fever and meningococcal meningitis.

38 om at-risk countries were vaccinated against yellow fever and polio.

39 th particular examples from studies with the yellow fever and the seasonal influenza vaccines.

40 ito-transmitted flaviviruses include dengue, yellow fever and Zika viruses.

41 and is the main worldwide vector of dengue, yellow fever, and chikungunya viruses.

42 e flaviviruses responsible for dengue fever, yellow fever, and chikungunya.

43 for other flaviviruses, including West Nile, yellow fever, and dengue viruses, and the critical role

44 genus Flavivirus, which includes West Nile, yellow fever, and tick-borne encephalitis viruses.

45 e flavivirus methyltransferases from dengue, yellow fever, and West Nile virus (WNV) sequentially gen

46 other Flaviviridae, including dengue, Zika, yellow fever, and West Nile virus, identifies conserved

47 anese encephalitis, tick-borne encephalitis, yellow fever, and West Nile viruses cause substantial mo

48 Zika virus is a flavivirus like the dengue, yellow fever, and West Nile viruses.

49 viral diseases (notably dengue, chikungunya, yellow fever, and Zika virus disease) resulting from the

50 tion serum samples for measles, rubella, and yellow fever; and the post-vaccination antibody titres g

51 The rubella and yellow fever antibody titres were reduced by co-administ

52 nohistochemical assay of liver tissue showed yellow fever antigen in the Kuppfer cells of the liver s

53 the XRX-001 vaccine, containing inactivated yellow fever antigen with an alum adjuvant, induced neut

54 est Nile fever, tick-borne encephalitis, and yellow fever, are endemic in tropical and temperate part

55 The yellow fever burden in Africa was estimated for the year

56 uito vectors of diseases such as malaria and yellow fever, but the molecular basis of CO(2) detection

57 ffective vaccine is available, the number of yellow fever cases has increased over the past two decad

58 Dengue, yellow fever, chikungunya, and Zika viruses have undergo

59 Mice were vaccinated with yellow fever, chimeric Japanese encephalitis virus (YF/J

60 ka virus, and the threat of global spread of yellow fever, combined with the resurgence of dengue and

61 vaccination coverage for polio, measles, and yellow fever continued to decrease, whereas the trend in

62 elping to allocate resources efficiently for yellow fever control.

63 urg, Lassa, the South American arenaviruses, yellow fever, Crimean-Congo and Rift Valley fever viruse

64 elicits a protective immune response against yellow fever, dengue, and tick-borne encephalitis flaviv

65 irus, which includes human pathogens such as yellow fever, Dengue, and West Nile virus.

66 It is closely related to yellow fever, dengue, Japanese encephalitis, and West Ni

67 It is closely related to the mosquito-borne yellow fever, dengue, Japanese encephalitis, and West Ni

68 ito-borne or tick-borne flaviviruses such as yellow fever, dengue, West Nile, St Louis encephalitis,

69 A chimeric yellow fever-dengue 1 (ChimeriVax-DEN1) virus was produc

70 14c10 light chain CDRs.IMPORTANCE A chimeric yellow fever-dengue live-attenuated tetravalent vaccine

71 eviously reported construction of a chimeric yellow fever-dengue type 2 virus (YF/DEN2) and determine

72 Sanofi Pasteur has developed a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue

73 Contemporary estimates of the yellow fever disease burden are lacking, and the present

74 The ongoing yellow fever epidemic in Angola strains the global vacci

75 egypti is the principal vector of dengue and yellow fever flaviviruses.

76 in the level of all vaccinations except for yellow fever for which the reduction was marginal.

77 Since late 2015, an epidemic of yellow fever has caused more than 7334 suspected cases i

78 human diseases such as malaria, dengue, and yellow fever has received much interest due to the abili

79 after a period of low vaccination coverage, yellow fever has resurged in the continent.

80 c diseases, such as cholera, meningitis, and yellow fever, have become common over the past decade, h

81 Substantial outbreaks of yellow fever in Angola and Brazil in the past 2 years, c

82 timate the effective reproductive number for yellow fever in Angola using disease natural history and

83 iseases (Chagas' disease, leishmaniasis, and yellow fever) in Colombia, we show the links between sys

84 in Africa during the 1940s to 1960s reduced yellow fever incidence for several decades.

85 nd of the Americans during the Cold War with yellow fever-infected mosquitoes.

86 treating West Nile Virus (WNV), Dengue, and Yellow Fever infections.

87 Yellow fever is a lethal viral hemorrhagic fever occurri

88 Yellow fever is a vector-borne disease affecting humans

89 Yellow fever is an acute viral hemorrhagic disease which

90 s a significant health burden in areas where yellow fever is endemic, but it is preventable through v

91 travelers to and residents of areas in which yellow fever is endemic, but the vaccine can cause serio

92 des aegypti, the global vector of dengue and yellow fever, is inexorably linked to water-filled human

93 Vaccines are available for yellow fever, Japanese encephalitis and tick-borne encep

94 West Nile fever (WNF), chikungunya, dengue, yellow fever, Japanese encephalitis virus, GBS, and cont

95 VPDs), including polio, measles and rubella, yellow fever, Japanese encephalitis, rotavirus, and inva

96 verified for their specificity in tests with yellow fever, Japanese encephalitis, St.

97 s including dengue fever, chikungunya, zika, yellow fever, leishmaniasis, chagas disease, and malaria

98 fection (hepatitis C virus) and vaccination (yellow fever, malaria, influenza), but poor outcome in a

99 B virus, and Haemophilus influenzae type b), yellow fever, measles, and tuberculosis.

100 by plaque reduction neutralisation (measles, yellow fever), microneutralisation (polio serotypes 1 an

101 This study tested this assumption using the yellow fever mosquito Aedes aegypti and malaria parasite

102 major downstream targets, S6 kinase, of the yellow fever mosquito Aedes aegypti during egg developme

103 The yellow fever mosquito Aedes aegypti forms aerial swarms

104 The yellow fever mosquito Aedes aegypti has been the subject

105 fficking, we disrupted COPI functions in the Yellow Fever mosquito Aedes aegypti to interfere with bl

106 e malaria mosquito Anopheles gambiae and the yellow fever mosquito Aedes aegypti were searched by Bla

107 to Anopheles gambiae REL1 (Gambif1) from the yellow fever mosquito Aedes aegypti, named AaREL1.

108 s in the genome of a divergent relative, the yellow fever mosquito Aedes aegypti.

109 malaria mosquito Anopheles stephensi and the yellow fever mosquito Aedes aegypti.

110 To reproduce, the female yellow fever mosquito has to find a human host.

111 Yellow fever mosquito sterol carrier protein (SCP-2) is

112 gand selectivity and in vivo function of the yellow fever mosquito sterol carrier protein-2 protein (

113 apidly displaced resident populations of the yellow fever mosquito, Aedes aegypti in the southeastern

114 ed neuropeptides in the antennal lobe of the yellow fever mosquito, Aedes aegypti, a major vector of

115 ivation of the vitellogenin (Vg) gene in the yellow fever mosquito, Aedes aegypti, by EcR/USP and E74

116 Prior studies with the yellow fever mosquito, Aedes aegypti, indicated blood fe

117 The yellow fever mosquito, Aedes aegypti, particularly in Ne

118 colactone may be an interkingdom cue for the yellow fever mosquito, Aedes aegypti, seeking blood-meal

119 site of ferritin expression and that, in the yellow fever mosquito, Aedes aegypti, the expression of

120 The yellow fever mosquito, Aedes aegypti, the global vector

121 from the nanos (nos) orthologous gene of the yellow fever mosquito, Aedes aegypti, to control sex- an

122 An intensive linkage map of the yellow fever mosquito, Aedes aegypti, was constructed us

123 By using the yellow fever mosquito, Aedes aegypti, we demonstrate tha

124 co-mediated activation of spermatozoa in the yellow fever mosquito, Aedes aegypti.

125 ystem in the fat body of fruit flies and the yellow fever mosquito, Aedes aegypti.

126 eviously sequenced an R2 cDNA clone from the yellow fever mosquito, Aedes aegypti.

127 ated SINEs named gecko was discovered in the yellow fever mosquito, Aedes aegypti.

128 initial steps of chitin biosynthesis in the yellow fever mosquito, Aedes aegypti.

129 genome, much less abundant than MITEs in the yellow fever mosquito, Aedes aegypti.

130 se mosquito, Culex quinquefasciatus, and the yellow fever mosquito, Aedes aegypti.

131 no-acid transporter Slimfast (Slif) from the yellow-fever mosquito Aedes aegypti using codon-optimize

132 We tested female yellow fever mosquitoes (Aedes aegypti) for responses to

133 ET-elicited protection against ZIKV-infected yellow fever mosquitoes from old and recent laboratory c

134 ully to remove a marker gene from transgenic yellow fever mosquitoes, Aedes aegypti.

135 evious estimates on the basis of more recent yellow fever occurrence data and improved estimation met

136 nfection have been found to cross-react with yellow fever- or dengue virus-positive sera.

137 graphic factors to the ongoing spread of the yellow fever outbreak and provide estimates of the areas

138 graphic factors to the ongoing spread of the yellow fever outbreak and provide estimates of the areas

139 were fitted to a dataset of the locations of yellow fever outbreaks within the last 25 years to estim

140 Yellow fever remains an important cause of illness and d

141 between 43% and 52% of the population within yellow fever risk zones, compared with between 66% and 7

142 still exist in contemporary coverage within yellow fever risk zones.

143 rus seroprevalence and measles, rubella, and yellow fever seroconversion, and (1/3) log2 for log2-tra

144 t human pathogens such as dengue, West Nile, yellow fever, tick-borne encephalitis and Japanese encep

145 With simple mathematical models of yellow fever transmission, we calculate the infection at

146 epidemics of human diseases such as malaria, yellow fever, typhus, and plague.

147 h-service-provider registeries) reporting on yellow fever vaccination activities between May 1, 1939,

148 e aims of this study were to estimate global yellow fever vaccination coverage from 1970 through to 2

149 ION: Our results highlight important gaps in yellow fever vaccination coverage, can contribute to imp

150 t) of 18 US clinics registered to administer yellow fever vaccination.

151 ts who developed severe illnesses days after yellow fever vaccination.

152 le causal relation between the illnesses and yellow fever vaccination.

153 The live yellow fever vaccine (YF-17D) offers a unique opportunit

154 The yellow fever vaccine (YFV) has been broadly used as a mo

155 dividuals immunized with the live attenuated yellow fever vaccine (YFV-17D) by sampling peripheral bl

156 The yellow fever vaccine 17D (17D) is safe, and after a sing

157 oenvironment to the response to the licensed yellow fever vaccine 17D (YF-17D) in an African cohort.

158 The live attenuated yellow fever vaccine 17D (YF-17D) is one of the most eff

159 The live attenuated yellow fever vaccine 17D (YF-17D) is one of the most eff

160 viral Ab responses, following infection with yellow fever vaccine 17D strain.

161 ology contain the nonstructural genes of the yellow fever vaccine and the premembrane and envelope ge

162 Vaccination with the yellow fever vaccine causes a systemic acute viral infec

163 on of the population who had ever received a yellow fever vaccine for each second level administrativ

164 Although a highly effective yellow fever vaccine has been available for more than se

165 ly dynamic in humans after subcutaneous live yellow fever vaccine immunization.

166 whole-virus, beta-propiolactone-inactivated yellow fever vaccine produced in Vero cell cultures and

167 2)-expressing plasmid (EP rDNA plus pIL-12), yellow fever vaccine virus 17D (rYF17D), and recombinant

168 The live-attenuated yellow fever vaccine virus 17D (YF17D) has many properti

169 We show that recombinant attenuated yellow fever vaccine virus 17D expressing simian immunod

170 eta production in response to CpG DNA or the yellow fever vaccine virus strain 17D.

171 The yellow fever vaccine YF-17D is one of the most successfu

172 For example, the yellow fever vaccine YF-17D, one of the most successful

173 d immune responses in humans vaccinated with yellow fever vaccine YF-17D.

174 o adjuvanted vaccines or the live-attenuated yellow fever vaccine.

175 , robust response to MRKAd5/HIV with that to yellow fever vaccine.

176 nteers immunized with the highly efficacious yellow fever vaccine.

177 patients found to be WNV IgM positive and no yellow fever vaccinees found to be WNV IgM positive.

178 IPV given alongside the measles-rubella and yellow fever vaccines at 9 months and when given as a fu

179 -administration of IPV, measles-rubella, and yellow fever vaccines within the Expanded Programme on I

180 ned to receive the IPV, measles-rubella, and yellow fever vaccines, singularly or in combination.

181 ent oral poliovirus (OPV), rubella, measles, yellow fever, varicella-zoster, multivalent measles/mump

182 ry gland anticoagulant from the mosquito and yellow fever vector Aedes albopictus, has been character

183 ified Wolbachia in Kenyan populations of the yellow fever vector Aedes bromeliae and its relative Aed

184 NAT subfamily from the larval midgut of the Yellow Fever vector mosquito, Aedes aegypti (aeAAT1, AAR

185 analysed datasets describing the epidemic of yellow fever, vector suitability, human demography, and

186 milar to that induced by the live attenuated yellow fever viral vaccine.

187 The ChimeriVax technology utilizes yellow fever virus (YF) 17D vaccine strain capsid and no

188 e a high mosquito infectivity phenotype, the yellow fever virus (YFV) 17D backbone of the ChimeriVax-

189 A neuroadapted strain of yellow fever virus (YFV) 17D derived from a multiply mou

190 The live attenuated yellow fever virus (YFV) 17D vaccine provides a good mod

191 phosphorylation sites of the NS5 proteins of yellow fever virus (YFV) and dengue virus (DENV), two fl

192 Previous studies of yellow fever virus (YFV) and dengue virus have found tha

193 tricts two medically important flaviviruses, yellow fever virus (YFV) and dengue virus serotype 2 (DE

194 Arboviruses such as yellow fever virus (YFV) are transmitted between arthrop

195 Yellow fever virus (YFV) can induce acute, life-threaten

196 Here we show that yellow fever virus (YFV) inhibits IFN-I signaling throug

197 Yellow fever virus (YFV) is the prototype member of the

198 sequencing is presented using as a model the yellow fever virus (YFV) live vaccine strain 17D-204 and

199 It was previously reported that mutations in yellow fever virus (YFV) nonstructural protein NS2A bloc

200 gue virus (DENV), West Nile virus (WNV), and yellow fever virus (YFV) NS1 attenuate classical and lec

201 verexpressed DNAJC14 is targeted to sites of yellow fever virus (YFV) replication complex (RC) format

202 Here we describe a two-component genome yellow fever virus (YFV) replication system in which eac

203 s-packaging system that involved packaging a yellow fever virus (YFV) replicon into pseudo-infectious

204 A molecular clone of yellow fever virus (YFV) strain 17D was used to identify

205 safety and immunogenicity of live attenuated yellow fever virus (YFV) vaccination of nonatopic subjec

206 In this study, we used the live attenuated yellow fever virus (YFV) vaccine 17D as a human in vivo

207 Here we address this issue using the live yellow fever virus (YFV) vaccine, which induces long-ter

208 Yellow fever virus (YFV), a member of the Flavivirus gen

209 ose of tick-borne encephalitis virus (TBEV), yellow fever virus (YFV), and Japanese encephalitis viru

210 th threats, including dengue viruses (DENV), yellow fever virus (YFV), and Zika virus (ZIKV).

211 of many important human pathogens including yellow fever virus (YFV), dengue virus (DENV), and Zika

212 that TRIM56 poses a barrier to infections by yellow fever virus (YFV), dengue virus serotype 2 (DENV2

213 involves the gene-specific amplification of yellow fever virus (YFV), Japanese encephalitis virus (J

214 Using yellow fever virus (YFV), we demonstrate that DNAJC14 re

215 + T cells specific for a single epitope from Yellow Fever Virus (YFV), we show that the recently desc

216 Mosquito-borne flaviviruses, including yellow fever virus (YFV), Zika virus (ZIKV), and West Ni

217 ine (BDAA) compound, which potently inhibits yellow fever virus (YFV).

218 Two yellow fever virus (YFV)/dengue virus chimeras which enc

219 A yellow fever virus (YFV)/Japanese encephalitis virus (JE

220 e insights into how a prototypic flavivirus, yellow fever virus (YFV-17D), differentially interacts w

221 ed mice before and after vaccination against yellow fever virus (YFV-17D).

222 DV, hepatitis C virus, West Nile virus, and yellow fever virus (YFV; vaccine strain 17D) were expres

223 wing ex vivo exposure to the live attenuated yellow fever virus 17D strain vaccine, a virus that we s

224 s of the flavivirus dengue virus (DV) and by yellow fever virus 17D were cholesterol independent, and

225 The capsid proteins of two flaviviruses, yellow fever virus and dengue virus, were expressed in E

226 ext of published studies of vaccines against yellow fever virus and influenza virus.

227 sis of CD8(+) T cells responding to the live yellow fever virus and smallpox vaccines--two highly suc

228 include the 2 flaviviruses dengue virus and yellow fever virus and the alphavirus chikungunya virus,

229 In contrast, yellow fever virus and West Nile virus were partially an

230 f 18 nucleotides (residues 146 to 163 of the yellow fever virus genome, which encode amino acids 9 to

231 ucleotide sequence found in the 5' region of yellow fever virus genomic RNA that is required for RNA

232 eplication of infectious West Nile virus and yellow fever virus in cell culture with low toxicity.

233 The data indicate that persistence of yellow fever virus in NB41A3 cells is associated with a

234 ogistic model to infer the district-specific yellow fever virus infection risk during the course of t

235 that the E protein is a critical factor for yellow fever virus neuropathogenesis in the SCID mouse m

236 Dengue, West Nile, or yellow fever virus NS1 directly associated with C4b bind

237 directed against a conserved immunodominant yellow fever virus NS3 epitope.

238 Structures of prM-containing dengue and yellow fever virus particles were determined to 16 and 2

239 protein) is essential for replication of the yellow fever virus replicon and that a slightly longer s

240 30451, specifically blocked translation of a yellow fever virus replicon but not a Sindbis virus repl

241 ed nucleotide and that the error rate of the yellow fever virus RNA polymerase employed by the chimer

242 ly proposed to be involved in cyclization of yellow fever virus RNA.

243 trative division across countries at risk of yellow fever virus transmission from 1970 to 2016.

244 till require vaccination in areas at risk of yellow fever virus transmission to achieve the 80% popul

245 This live attenuated yellow fever virus vaccine yields sterile, long-term imm

246 The early spread of yellow fever virus was characterised by fast exponential

247 Vaccine-related variants of yellow fever virus were found in plasma and cerebrospina

248 ax-II), rotavirus (Rotateq and Rotarix), and yellow fever virus were negative for XMRV and highly rel

249 ift Valley fever virus, West Nile virus, and yellow fever virus), 8 bacteria (Bartonella spp., Brucel

250 us, Murray Valley virus, Powassan virus, and yellow fever virus).

251 ding vesicular stomatitis virus, poliovirus, yellow fever virus, and herpes simplex virus type 1, rep

252 Arboviruses like dengue virus, yellow fever virus, and West Nile virus are enveloped pa

253 ncluding all four serotypes of dengue virus, yellow fever virus, and West Nile virus.

254 curred in NS2B-NS3 recombinant proteins from yellow fever virus, dengue virus types 2 and 4, and Japa

255 ing three members of the family Flaviviridae(yellow fever virus, dengue virus, and bovine viral diarr

256 Flaviviruses, such as Zika virus, yellow fever virus, dengue virus, and West Nile virus (W

257 Vaccine strains of yellow fever virus, isolated from the plasma of two pati

258 ephalitis virus, norovirus, metapneumovirus, yellow fever virus, Japanese encephalitis virus, parainf

259 d mosquito-borne flaviviruses, which include yellow fever virus, Sepik virus, Saboya virus, and other

260 wide range of viruses, including DENV, WNV, yellow fever virus, Sindbis virus, Venezuelan equine enc

261 animal viruses, including hepatitis C virus, yellow fever virus, West Nile virus, chikungunya virus,

262 cutive plaque purifications of four chimeric yellow fever virus-dengue virus (ChimeriVax-DEN) vaccine

263 Two forms of NS2A are found in yellow fever virus-infected cells.

264 s, including pathogens such as influenza and yellow fever virus.

265 rica to understand and predict the spread of yellow fever virus.

266 EN) 4 virus was chimerized with the WT Asibi yellow fever virus.

267 es or West Nile virus, or vaccinated against yellow fever virus.

268 iated mosquito-borne flaviviruses, including yellow fever virus.

269 However, dengue, chikungunya, and yellow fever viruses have repeatedly initiated urban tra

270 The past evolution of the dengue and yellow fever viruses provides clues about the influence

271 vectors of African malaria, dengue fever and yellow fever viruses, and lymphatic filariasis, respecti

272 nd other flaviviruses, such as West Nile and yellow fever viruses, contain a 5' m7GpppN-capped positi

273 o many flavivirus types including Dengue and yellow fever viruses, the nonstructural NS3 multifunctio

274 ot neutralize or immune-precipitate mumps or yellow fever viruses.

275 diseases that include West Nile, dengue and yellow fever viruses.

276 of other flaviviruses, including dengue and yellow fever viruses.

277 nction of NS4B is conserved in West Nile and yellow fever viruses.

278 r medically-important flaviviruses including yellow fever, West Nile and Japanese encephalitis viruse

279 transmits two major arboviruses, dengue and yellow fever, which cause significant global morbidity a

280 vaccine against Japanese encephalitis, using yellow fever (YF) 17D vaccine as a vector.

281 The yellow fever (YF) 17D vaccine is one of the most success

282 cine constructed from an infectious clone of yellow fever (YF) 17D virus in which the premembrane and

283 premembrane (prM) and envelope (E) genes of yellow fever (YF) 17D virus were replaced with those of

284 d Japanese encephalitis vaccination enhanced yellow fever (YF) immunogenicity upon YF vaccination.

285 te the availability of an effective vaccine, yellow fever (YF) is considered a reemerging disease owi

286 Yellow fever (YF) is still a major public health problem

287 The attenuated yellow fever (YF) vaccine (YF-17D) was developed in the

288 induced by immunization with live-attenuated yellow fever (YF) vaccine.

289 All currently licensed yellow fever (YF) vaccines are propagated in chicken emb

290 ted intraperitoneally with 10(6) TCID(50) of yellow fever (YF) virus (Jimenez strain).

291 relationships among flaviviruses within the yellow fever (YF) virus genetic group were investigated

292 A hamster viscerotropic strain of yellow fever (YF) virus has been derived after serial pa

293 ve indicated that there are two genotypes of yellow fever (YF) virus in Africa, one in west Africa an

294 e cap-binding pocket of the dengue (DEN) and yellow fever (YF) virus MTase enzymes.

295 We have genetically engineered an attenuated yellow fever (YF) virus to carry and express foreign ant

296 golden hamsters experimentally infected with yellow fever (YF) virus.

297 A chimeric yellow fever (YF) virus/Japanese encephalitis (JE) virus

298 (TBE), dengue fever (DF), West Nile (WN) and yellow fever (YF), can aid in the design of antiviral dr

299 Providers must counsel travelers to yellow fever (YF)-endemic areas, although risk estimates

300 regions, is the principal vector of dengue, yellow fever, Zika and Chikungunya viruses.